MedTrace Logo

Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women

NCT00961272 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2014-02-28

No results posted yet for this study

Summary

The purpose of this study is to characterize the pharmacokinetics of raltegravir in cervicovaginal fluids as compared to blood plasma of HIV-infected pre-menopausal women.

Conditions

  • HIV Infections

Sponsors & Collaborators

Principal Investigators

  • Kristine Patterson, MD · University of North Carolina, Chapel Hill

  • Angela Kashuba, PharmD · University of North Carolina, Chapel Hill

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961272 on ClinicalTrials.gov